Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer-Reference-Cited by-同舟云学术

Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer

Published:2021-11-17 Issue:1 Volume:33 Page:97-98
ISSN:0956-4624
Container-title:International Journal of STD & AIDS
language:en
Short-container-title:Int J STD AIDS

Author:

Roa Pia-Allison E¹,Bazzi Rima¹^ORCID

Affiliation:

1. Department of Pharmacy Resident, Beaumont Hospital, Dearborn, MI, USA

Abstract

We present the case of a 78-year-old African American man with a history of human immunodeficiency virus diagnosed in 2007 who was newly diagnosed with pancreatic cancer. A percutaneous endoscopic gastrostomy tube was placed during the initial inpatient visit of pancreatic cancer diagnosis due to persistent dysphagia. Due to PEG placement and the patient’s wish to continue his previous antiretroviral therapy, the patient crushed his fixed-dose bictegravir/emtricitabine/tenofovir alafenamide under the direction of a physician and has maintained virologic suppression.

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Public Health, Environmental and Occupational Health,Dermatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/09564624211048702

Reference9 articles.

1. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of health and human services. Available at: https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultandAdolescentGL.pdf Accessed June 21, 2021.

2. Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV

3. Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration

4. Virological suppression after use of crushed tenofovir–emtricitabine and dolutegravir tablets in a patient with HIV infection

5. Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Modern Antiretroviral Therapy in the Intensive Care Unit: Overcoming Challenges for Critically Ill People With Human Immunodeficiency Virus;Open Forum Infectious Diseases;2024-04-17

2. Evaluation of Dolutegravir- and Bictegravir-Based Antiretroviral Regimen Utilization in Patients who Cannot Take Medications by Mouth;Open Forum Infectious Diseases;2023-11-11

3. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study;Journal of Antimicrobial Chemotherapy;2022-11-02

4. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection;Retrovirology;2022-10-22